Cancer Treatment News and Research

RSS

Fatigue before cancer treatment impacts fatigue afterwards

Individuals who survive cancer are significantly more likely to develop severe persistent fatigue a year after treatment if they were fatigued before and shortly after treatment, indicate Dutch study findings.

28 Feb 2013

Herceptin may have greater role in treating HER2-negative breast cancer

New research from the University of Michigan Comprehensive Cancer Center finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative - and that the drug Herceptin, which targets HER2, may have an even greater role for treating breast cancer and preventing its spread.

28 Feb 2013

Trends in patient worry and risk-reducing behaviors in women undergoing breast cancer treatment

Women who have had the lymph nodes under their arm surgically removed during breast cancer treatment are warned to avoid certain practices that can cause lymphedema-a condition that causes chronic, painless swelling in the arm.

26 Feb 2013

Two discriminating biological markers found to predict a favorable response to treatment in triple-negative breast cancer

Quinten, a strategic and operational consulting company specializing in the evaluation of biomedical data in the pharmaceutical, biotechnology and cosmetic industries, today announces the identification of two discriminating biological marker candidates which are indicative of a favorable response to treatment in women suffering from triple-negative breast cancer (TNBC).

26 Feb 2013

Dana-Farber launches iPhone app that helps fight cancer

Dana-Farber Cancer Institute has launched a free, easy-to-use iPhone app that provides recipes and nutrition information that can be searched by cancer patients in accordance with their needs.

25 Feb 2013

Marine-based active substances show promise against multiple myeloma

There is fierce competition in the ocean habitat. In order to survive there, marine organisms defend themselves against their rivals using an entire arsenal of chemical weapons. With the help of these substances they attack hostile cells, overcome their defence system and thus are interesting active substance candidates for cancer research.

22 Feb 2013

Childhood cancer on the rise across the developing world

Across the developing world, childhood cancer is on the rise, and mortality is high. Once thought of as a rich world disease, cancer is a growing health threat across low-income and middle-income countries (LMCs). A major new Lancet Oncology Series by some of the world’s most eminent cancer experts outlines the biggest challenges to treating childhood cancer in developing nations and proposes strategies to improve care for children and young people.

20 Feb 2013

Child cancer survival rate progress threatened by lack of new drug development

Remarkable improvements in survival from childhood cancer have taken place in high- income countries over the past 50 years, but further progress is being threatened by increasingly strict research regulations and insufficient development of new drugs, according to a major new Lancet Oncology Series on improving cancer care for children and young people.

20 Feb 2013

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

ADCs are used for a new type of targeted therapy that consists of a specific anti-cancer antibody or antibody fragment linked to a potent anti-cancer therapeutic.

20 Feb 2013

Internationally-recognized cancer clinician named first K. Hasumi Professor of Medical Oncology

Internationally-recognized cancer clinician and researcher Takami Sato, M.D., Ph.D., who serves as the Director of the Metastatic Uveal Melanoma Program in the Department of Medical Oncology at Thomas Jefferson University, has been named the first K. Hasumi Professor of Medical Oncology.

20 Feb 2013

Surveying the landscape from bench to bedside

The Obama administration is planning a decade-long scientific effort to examine the workings of the human brain and build a comprehensive map of its activity, seeking to do for the brain what the Human Genome Project did for genetics.

20 Feb 2013

Therapy to ease QOL issues improves patients' sense of well-being during cancer treatment

Therapy to ease stress, fatigue and other quality of life issues significantly improves patients' sense of well-being during cancer treatment, new Mayo Clinic research shows. Patients who kept to their standard routines showed a decline in quality-of-life measures, the study found. The findings are published this month in Cancer.

19 Feb 2013

First Edition: February 19, 2013

Kaiser Health News staff writer Jay Hancock, working in collaboration with The Philadelphia Inquirer, reports: "Computer mistakes like the one that produced incorrect prescriptions for thousands of Rhode Island patients are probably far more common and dangerous than the Obama administration wants you to believe, says Drexel University's Dr. Scot Silverstein."

19 Feb 2013

Researchers discover genetic defect that can halt cell growth

A Melbourne-based research team has discovered a genetic defect that can halt cell growth and force cells into a death-evading survival state.

18 Feb 2013

Shorter version of abPG-SGA can potentially improve outcomes for cancer patients

Considering the many things a cancer patient has to think about, it's easy to understand why maintaining proper nutrition may not be top of mind. This can be true, too, at busy outpatient settings where it's often difficult to find the time and resources to test cancer patients for malnutrition.

18 Feb 2013

Research involves new, safer ways to deliver biomedical agents against tumors

Jeremy L. Steinbacher, PhD, is among a new generation of scientists trying to improve their aim and approach to killing cancer cells. The Canisius College professor of chemistry/biochemistry is working to develop biomedical agents that more accurately target and attack tumors.

16 Feb 2013

Researchers solve complete 3-D structure of E6 proteins in HPV 16

For the first time, researchers from the Laboratoire biotechnologie et signalisation cellulaire at the Strasbourg-based Ecole supérieure de biotechnologie (CNRS/Université de Strasbourg) and Institut de génétique et de biologie moléculaire et cellulaire (CNRS/Université de Strasbourg/Inserm) have solved the three-dimensional structure of an important oncoprotein involved in cell proliferation and in the development of the human papilloma virus (HPV).

14 Feb 2013

Will more availability of some Medicare therapies spark a budget crisis?

Politico looks at how making some therapies more widely available to Medicare recipients -- as one lawsuit is asking for -- could strain the program's budget. In addition, The Associated Press examines Medicare records to find that monitoring some kidney cancer patients instead of operating could improve their chances to live.

14 Feb 2013

Ability to tune gene activity will permit refined research for drug resistance, cancer

Scientists who built a synthetic gene circuit that allowed for the precise tuning of a gene's expression in yeast have now refined this new research tool to work in human cells, according to research published online in Nature Communications.

13 Feb 2013

New drug delivery system can reduce size of ovarian tumors by as much as 83%

By loading fragile RNA into silicon nanoparticles, researchers from The Methodist Hospital and two other institutions found a new drug delivery system can reduce the size of ovarian tumors by as much as 83 percent -- and stop tumor growth in chemotherapy-resistant ovarian cancer tissue.

13 Feb 2013